Company profile
Syndax Pharmaceuticals, Inc.
NASDAQ: SNDX · Healthcare · Biotechnology
PublicHQ New York City, MACIK 0001395937Reports USD
#300 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
52DFH 36DQ 73GM 49SS 70
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), filing timeliness · ↓ growth stability, return on equity
Methodology →Revenue TTM
$217.2M
Rev growth YoY (TTM)
+396.7%
Net income (FY)
-$285.4M
Employees
298
as of 2026-08-09
Market cap
$1.8B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$172.4M$172.4M2025
Net income-$285.4M-$285.4M2025
Operating income-$273.1M-$273.1M2025
Total assets$529.7M$529.7M2025
Liabilities$465.1M$465.1M2025
Equity$64.6M$64.6M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Net Product Revenues72%
Collaboration revenue25%
Milestone Revenue3%
By geography
Not disclosed.
The read
What is Syndax Pharmaceuticals, Inc.’s revenue?
Syndax Pharmaceuticals, Inc. booked $172.4M in FY2025 revenue, growing 628% year over year — faster than 95% of Healthcare companies we track, at a -165.6% net margin.
Peers · Healthcare
Stoke Therapeutics, Inc.60CHeartflow, Inc. Common Stock44DPhathom Pharmaceuticals, Inc.47DREGENXBIO Inc.54DGinkgo Bioworks Holdings, Inc.44DMaze Therapeutics, Inc.49DKey facts
CEOMichael A. Metzger
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, MA
ExchangeNASDAQ: SNDX
Employees298
IPO date2016-03-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.